August 14th 2025
The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.
The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation
Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care
QCCA, NCCA Merge to Form ONCare Among Independent Oncology Practices
Getting to Know Dr Chandler Cortina, Breast Surgical Oncologist
COA's Dr Miriam Atkins: PBMs, HR 5526, and Marketplace Strategy